Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
Streptococcal fibrinolysin . An enzyme produced by hemolytic streptococci. It hydrolyzes amide linkages and serves as an activator of plasminogen. It is used in thrombolytic therapy and is used also in mixtures with streptodornase (STREPTODORNASE AND STREPTOKINASE). EC 3.4.-.
A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.
The natural enzymatic dissolution of FIBRIN.
Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts.
A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.
Exclusive legal rights or privileges applied to inventions, plants, etc.
A genus of venomous snakes of the subfamily Crotalinae. Twelve species of this genus are found in North and Central America and Asia. Agkistrodon contortrix is the copperhead, A. piscivorus, the cottonmouth. The former is named for its russet or orange-brown color, the latter for the white interior of its mouth. (Goin, Goin, and Zug, Introduction to Herpetology, 3d ed, p336; Moore, Poisonous Snakes of the World, 1980, p75)
Venoms obtained from Apis mellifera (honey bee) and related species. They contain various enzymes, polypeptide toxins, and other substances, some of which are allergenic or immunogenic or both. These venoms were formerly used in rheumatism to stimulate the pituitary-adrenal system.
Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders.
The medical use of honey bee products such as BEE VENOM; HONEY; bee pollen; PROPOLIS; and royal jelly.
Basic polypeptide from the venom of the honey bee (Apis mellifera). It contains 26 amino acids, has cytolytic properties, causes contracture of muscle, releases histamine, and disrupts surface tension, probably due to lysis of cell and mitochondrial membranes.
Family of INSECT VIRUSES containing two subfamilies: Eubaculovirinae (occluded baculoviruses) and Nudibaculovirinae (nonoccluded baculoviruses). The Eubaculovirinae, which contain polyhedron-shaped inclusion bodies, have two genera: NUCLEOPOLYHEDROVIRUS and GRANULOVIRUS. Baculovirus vectors are used for expression of foreign genes in insects.
A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.
Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.
Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.
Plastic tubes used for drainage of air or fluid from the pleural space. Their surgical insertion is called tube thoracostomy.
Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.
The removal of fluids or discharges from the body, such as from a wound, sore, or cavity.
Suppurative inflammation of the pleural space.
An accumulation of air or gas in the PLEURAL CAVITY, which may occur spontaneously or as a result of trauma or a pathological process. The gas may also be introduced deliberately during PNEUMOTHORAX, ARTIFICIAL.
Fluid accumulation within the PERICARDIUM. Serous effusions are associated with pericardial diseases. Hemopericardium is associated with trauma. Lipid-containing effusion (chylopericardium) results from leakage of THORACIC DUCT. Severe cases can lead to CARDIAC TAMPONADE.
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
The veins and arteries of the HEART.
Radiography of the vascular system of the heart muscle after injection of a contrast medium.
Generally, restoration of blood supply to heart tissue which is ischemic due to decrease in normal blood supply. The decrease may result from any source including atherosclerotic obstruction, narrowing of the artery, or surgical clamping. Reperfusion can be induced to treat ischemia. Methods include chemical dissolution of an occluding thrombus, administration of vasodilator drugs, angioplasty, catheterization, and artery bypass graft surgery. However, it is thought that reperfusion can itself further damage the ischemic tissue, causing MYOCARDIAL REPERFUSION INJURY.
The circulation of blood through the CORONARY VESSELS of the HEART.
Formation and development of a thrombus or blood clot in the blood vessel.
A state in south central Australia. Its capital is Adelaide. It was probably first visited by F. Thyssen in 1627. Later discoveries in 1802 and 1830 opened up the southern part. It became a British province in 1836 with this self-descriptive name and became a state in 1901. (From Webster's New Geographical Dictionary, 1988, p1135)
An approach of practicing medicine with the goal to improve and evaluate patient care. It requires the judicious integration of best research evidence with the patient's values to make decisions about medical care. This method is to help physicians make proper diagnosis, devise best testing plan, choose best treatment and methods of disease prevention, as well as develop guidelines for large groups of patients with the same disease. (from JAMA 296 (9), 2006)
Agents that prevent clotting.
Time period from 1801 through 1900 of the common era.
The study of the structure, growth, function, genetics, and reproduction of bacteria, and BACTERIAL INFECTIONS.
A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.
A publication issued at stated, more or less regular, intervals.
Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.
Four CSF-filled (see CEREBROSPINAL FLUID) cavities within the cerebral hemispheres (LATERAL VENTRICLES), in the midline (THIRD VENTRICLE) and within the PONS and MEDULLA OBLONGATA (FOURTH VENTRICLE).
"The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.
An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
Dilation of an occluded coronary artery (or arteries) by means of a balloon catheter to restore myocardial blood supply.
Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.
A family of percutaneous techniques that are used to manage CORONARY OCCLUSION, including standard balloon angioplasty (PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY), the placement of intracoronary STENTS, and atheroablative technologies (e.g., ATHERECTOMY; ENDARTERECTOMY; THROMBECTOMY; PERCUTANEOUS TRANSLUMINAL LASER ANGIOPLASTY). PTCA was the dominant form of PCI, before the widespread use of stenting.
A characteristic symptom complex.
Excessive accumulation of cerebrospinal fluid within the cranium which may be associated with dilation of cerebral ventricles, INTRACRANIAL HYPERTENSION; HEADACHE; lethargy; URINARY INCONTINENCE; and ATAXIA.
The condition of an anatomical structure's being dilated beyond normal dimensions.
The washing of a body cavity or surface by flowing water or solution for therapy or diagnosis.
The routing of water to open or closed areas where it is used for agricultural purposes.
A human infant born before 37 weeks of GESTATION.
The application of scientific knowledge to practical purposes in any field. It includes methods, techniques, and instrumentation.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.

Optimal thrombolytic strategies for acute myocardial infarction--bolus administration. (1/3072)

Optimal strategies for thrombolysis in myocardial infarction (TIMI) are still being sought because the TIMI 3 flow rates achievable using standard regimens average approximately 60%. Double bolus administration of recombinant tissue plasminogen activator (tPA) is a novel approach with potential for earlier patency combined with ease of administration. We reviewed total patency rates, TIMI 3 patency rates, mortality, stroke and intracranial haemorrhage rates in the major trials of accelerated infusion tPA/bolus tPA/reteplase in acute myocardial infarction. A direct comparison was performed with results of two recent trials of double bolus (two 50 mg boli, 30 min apart) vs. accelerated infusion tPA: the Double Bolus Lytic Efficacy Trial (DBLE), an angiographic study, and the COBALT Trial, a mortality study. The DBLE trial showed equivalent patency rates for accelerated infusion and double bolus administration of tPA. Reviewing other angiographic trials, total patency and TIMI 3 patency rates achievable with double bolus tPA were comparable to those with accelerated infusion tPA or bolus reteplase administration. The COBALT study demonstrated a 30-day mortality of 7.53% in patients treated with accelerated infusion tPA compared with 7.98% for double bolus tPA treated patients. The small excess in mortality with double bolus treatment was confined to the elderly; in those < or = 75 years, mortality rates were 5.6% and 5.7%, for double bolus and accelerated infusion, respectively, and rates for death or non-fatal stroke were 6.35% and 6.3%, respectively. Comparison with other trials demonstrated mortality, stroke and intracranial haemorrhage rates with double bolus treatment similar to those associated with either accelerated infusion tPA or bolus reteplase treatment. Double bolus administration of tPA to patients with acute myocardial infarction is associated with total patency, TIMI 3 patency, mortality, stroke and intracranial haemorrhage rates similar to those associated with either accelerated infusion of tPA or bolus reteplase.  (+info)

Isolation of SMTP-3, 4, 5 and -6, novel analogs of staplabin, and their effects on plasminogen activation and fibrinolysis. (2/3072)

Four novel triprenyl phenol metabolites, designated SMTP-3, -4, -5, and -6, have been isolated from cultures of Stachybotrys microspora IFO 30018 by solvent extraction and successive chromatographic fractionation using silica gel and silica ODS columns. A combination of spectroscopic analyses showed that SMTP-3, -4, -5, and -6 are staplabin analogs, containing a serine, a phenylalanine, a leucine or a tryptophan moiety in respective molecules in place of the N-carboxybutyl portion of the staplabin molecule. SMTP-4, -5, and -6 were active at 0.15 to 0.3 mM in enhancing urokinase-catalyzed plasminogen activation and plasminogen binding to fibrin, as well as plasminogen- and urokinase-mediated fibrinolysis. On the other hand, the concentration of staplabin required to exert such effects was 0.4 to 0.6 mM, and SMTP-3 was inactive at concentrations up to 0.45 mM.  (+info)

Two similar cases of encephalopathy, possibly a reversible posterior leukoencephalopathy syndrome: serial findings of magnetic resonance imaging, SPECT and angiography. (3/3072)

Two young women who had encephalopathy that resembled reversible posterior leukoencephalopathy syndrome are presented. The brain magnetic resonance imaging (MRI) of these patients exhibited similar T2-high signal lesions, mostly in the white matter of the posterior hemispheres. Xe-SPECT during the patients' symptomatic period showed hypoperfusion in the corresponding areas, and angiography demonstrated irregular narrowing of the posterior cerebral artery. Clinical manifestations subsided soon after treatment, and the abnormal radiological findings also were almost completely resolved. Thus, we concluded that transient hypoperfusion followed by ischemia and cytotoxic edema might have had a pivotal role in these cases.  (+info)

Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. (4/3072)

Fasudil hydrochloride is a new type of intracellular calcium antagonist, different from the calcium entry blockers that are commonly employed for clinical use. Since September 1995, the combination of fasudil hydrochloride and ozagrel sodium, an inhibitor of thromboxane A2 synthesis, has been used to treat 60 patients at risk of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. The effectiveness of this combination therapy was investigated by comparison with the outcome of 57 patients previously treated with only ozagrel sodium. The combination therapy was significantly more effective (p < 0.01) in reducing the incidence of low density areas on computed tomography scans, and reduced, but not significantly, the occurrence of symptomatic vasospasm. The combination therapy of fasudil hydrochloride and ozagrel sodium has superior effectiveness over only ozagrel sodium in treating patients at risk of vasospasm after aneurysmal subarachnoid hemorrhage.  (+info)

Cerebral venous thrombosis: combined intrathrombus rtPA and intravenous heparin. (5/3072)

BACKGROUND AND PURPOSE: We chose to evaluate the safety and efficacy of combined intrathrombus rtPA and intravenous heparin in cerebral venous thrombosis (CVT). METHODS: We treated 12 patients with symptoms of 1 to 40 days' duration (eg, headache, somnolence, focal deficits, seizures, and nausea and vomiting). Pretreatment MRI disclosed subtle hemorrhagic venous infarction in 4 patients, obvious hemorrhagic infarction in 2, small parenchymal hemorrhage from recent pallidotomy in 1, and no focal lesion in 5. Magnetic resonance venography and contrast venography identified thrombi in the superior sagittal sinus (SSS) in 3 patients; transverse/sigmoid sinus (TS/SS) in 2; SSS and both TS/SS in 1; SSS and 1 TS/SS in 5; and SSS, 1 TS/SS, and straight sinus in 1 patient. A loading dose of rtPA was instilled throughout the clot at 1 mg/cm, followed by continuous intrathrombus infusion at 1 to 2 mg/h. Intravenous heparin was infused concomitantly. RESULTS: Flow was restored completely in 6 patients and partially in 3, with a mean rtPA dose of 46 mg (range, 23 to 128 mg) at a mean time of 29 hours (range, 13 to 77 hours). Symptoms improved in these 9 patients concomitantly with flow restoration. Flow could not be restored in 3 patients. In 1 of them, treatment was stopped when little progress had been made, and fibrinogen level dropped to 118 mg/dL. In the other 2 patients, hemorrhagic worsening occurred, and treatment was abbreviated after initial rtPA dosing. In 1 of these, the hematoma was evacuated. CONCLUSIONS: Our experience with intrathrombus rtPA in conjunction with intravenous heparin in patients with CVT is encouraging. This therapy should probably be regarded as unsafe in patients with obvious hemorrhage. Time to restore flow may be faster than with urokinase (an average of 71 hours has been reported for 29 documented patients). Further evaluation of rtPA with heparin in CVT is warranted.  (+info)

Delayed increase in infarct volume after cerebral ischemia: correlations with thrombolytic treatment and clinical outcome. (6/3072)

BACKGROUND AND PURPOSE: Growing experimental evidence indicates that the development of cerebral ischemic damage is slower than previously believed. The aims of this work were (1) to study the evolution of CT hypoattenuation between 24 to 36 hours and 7 days in ischemic stroke patients; (2) to evaluate whether thrombolytic treatment given within 6 hours of stroke affects delayed infarction evolution; and (3) to investigate possible correlations between lesion volume changes over time and clinical outcome. METHODS: Of 620 patients included in the European Cooperative Acute Stroke Study 1 (ECASS1), we selected 450 patients whose control CT scans at day 1 (CT1) and day 7 (CT7) were available. They had been randomly divided into 2 groups: 206 patients had been treated with rtPA and 244 with placebo. CT1 and CT7 were classified according to the location of the infarct. The volume of CT hypoattenuation was measured using the formula AxBxC/2 for irregular volumes. The 95% confidence interval of inter- and intrarater variability was used to determine whether significant changes in lesion volume had occurred between CT1 and CT7. Clinical severity was evaluated by means of the Scandinavian Stroke Scale (SSS) at entry (SSS0) and at day 30 (SSS30). RESULTS: Mean lesion volumes were significantly (P<0.0001) higher at day 7 than at day 1 in all the subgroups of patients and particularly in patients with a subcortical lesion. Of the 450 patients studied, 287 (64%) did not show any significant change in lesion volume between CT1 and CT7, 143 (32%) showed a significant increase and the remaining 20 (4%) a significant decrease. No significant correlation was observed between treatment and lesion evolution between CT1 and CT7. Both clinical scores (SSS0 and SSS30) and degree of neurological recovery were significantly (P<0.05) lower in the subgroup of patients with a significant lesion volume increase than in the other 2 groups. CONCLUSIONS: In approximately two thirds of patients, infarct size is established 24 to 36 hours after stroke onset, whereas in the remaining one third, changes in lesion volume may occur later than the first 24 to 36 hours. Many factors may be responsible for delayed infarct enlargement and for a lower degree of clinical recovery, both of which may occur despite early recombinant tissue plasminogen activator treatment.  (+info)

Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. (7/3072)

BACKGROUND AND PURPOSE: We tested the hypothesis that treatment of embolic stroke with recombinant human tissue plasminogen activator (rhtPA) alters cerebral expression of adhesion molecules. METHODS: Male Wistar rats were subjected to middle cerebral artery occlusion by a single fibrin-rich clot. P-selectin, E-selectin, and intercellular adhesion molecule-1 (ICAM-1) immunoreactivity was measured at 6 or 24 hours after embolic stroke in control rats and in rats treated with rhtPA at 1 or 4 hours after stroke. To examine the therapeutic efficacy of combined rhtPA and anti-ICAM-1 antibody treatment at 4 hours after embolization, ischemic lesion volumes were measured in rats treated with rhtPA alone, rats treated with rhtPA and anti-ICAM-1 antibody, and nontreated rats. RESULTS: Administration of rhtPA at 1 hour after embolization resulted in a significant reduction of adhesion molecule vascular immunoreactivity after embolization in the ipsilateral hemisphere compared with corresponding control rats. However, when rhtPA was administered to rats at 4 hours after embolization, significant increases of adhesion molecule immunoreactivity in the ipsilateral hemisphere were detected. A significant increase of ICAM-1 immunoreactivity was also detected in the contralateral hemisphere at 24 hours after ischemia. A significant reduction in lesion volume was found in rats treated with the combination of rhtPA and anti-ICAM-1 antibody compared with rats treated only with rhtPA. CONCLUSIONS: The present study suggests that the time of initiation of thrombolytic therapy alters vascular immunoreactivity of inflammatory adhesion molecules in the ischemic brain and that therapeutic benefit can be obtained by combining rhtPA and anti-ICAM-1 antibody treatment 4 hours after stroke.  (+info)

Intra-arterial rtPA treatment of stroke assessed by diffusion- and perfusion-weighted MRI. (8/3072)

BACKGROUND: Diffusion-weighted MRI (DWI) and perfusion-weighted MRI (PWI) are new techniques that can be used for the evaluation of acute ischemic stroke. However, their potential role in the management of patients treated with recombinant tissue plasminogen activator (rtPA) has yet to be determined. CASE DESCRIPTION: The authors present the case of a 73-year-old man who was treated with intra-arterial rtPA, and they compare findings on DWI and PWI scans with angiography. PWI revealed decreased cerebral perfusion corresponding to an area that was not successfully recanalized, but revealed no abnormality in regions in which blood flow was restored. DWI was unremarkable in the region that was reperfused early (3 hours) but revealed hyperintensity in an area that was reperfused 3. 5 hours after symptom onset and in the area that was not reperfused. CONCLUSIONS: Findings on PWI correlated well with angiography, and DWI detected injured tissue in the hyperacute stage, whereas conventional MRI findings were negative. This suggests that these techniques may be useful to noninvasively evaluate the success of thrombolytic therapy.  (+info)

Use of antithrombotic medications increases risk of hematuria-related complications answers are found in the EE+ POEM Archive powered by Unbound Medicine. Available for iPhone, iPad, Android, and Web.
Antithrombotic Drugs Market 2017-2027 : Anticoagulants, Antiplatelets, Fibrinolytics The revenue of the antithrombotic drugs market in 2016 is estimated at $18.
Abbildung 3: Ergebnisse der JUMBO-TIMI-26-Studie (p < 0,05: signifikant; MACE: major adverse cardiac event nach 30 Tagen; MI: Myokardinfarkt nach 30 Tagen; CTVT: clinical target vessel thrombosis nach 30 Tagen. Mod. nach [Wiviott S, Antman E, Winters K, Weerakkody G, Murphy S, Behounek B, Carney R, Lazzam C, McKay R, McCabe C, Braunwald E; JUMBO TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111: 3366 73 ...
Results Patients who received supportive treatment with heparin had significantly higher occurrences of any (OR, 2.46; 95% CI, 1.15 to 5.28) and symptomatic ICH (OR, 3.71; 95% CI, 1.18 to 14.95). Additionally, these patients were less likely to have a moderate clinical outcome after 90 days (modified Rankin scale 0-3; OR, 0.33; 95% CI, 0.15 to 0.72), but were more likely to have a fatal outcome after 90 days (OR, 2.84; 95% CI 1.10 to 7.31). These findings persisted in patients who received both DAT and heparin, but not for patients who received both tirofiban and heparin. ...
Frozen and lyophilized compositions for a metalloproteinase fibrinolytic agent (fibrolase or NAT), a method for preparing the lyophilized composition, and a kit and method for reconstituting the lyophilized composition are described herein.
Data was collected on each patient, a study investigator with stroke expertise analyzed the images for classification into the various groups (lobar, non-lobar, unclassifiable, or multiple), and antithrombotic drug was categorized by type (antiplatelet, antithrombotic, or both). Case fatality rate was recorded at 30 days. Patients taking antithrombotic drugs had higher case fatality rate at 30 days, overall, when compared to patients not taking antithrombotics. Bivariate analysis revealed that restarting antithrombotics was more likely in younger patients, but median ICH volume was not found to differ between survivors who restarted or stopped antithrombotic agents. The proportion of patients restarting was also highest in those who were taking vitamin K antagonists before ICH. The strengths of the study included the large sample size and inclusion of multiple cohorts representing different settings. The variation between patients suggested that the cohort of origin played a role and the authors ...
Despite the interesting conclusions of the PRAGUE-14 study, the article fails to show important information that might be required to draw the right conclusions. First, while it is known that the impact of cessation of antithrombotic therapy partly depends on the preoperative health status of the patient, the authors refrained from presenting data on the specific interaction between preoperative comorbidities and the decision to stop antithrombotic therapy, in particular in light of a bridging protocol. For instance, the authors suggest in the discussion that previous percutaneous coronary intervention with coronary stent implantation is an independent risk factor for perioperative complications. However, it is unclear from their study whether they included patients with a coronary stent who stopped antithrombotic therapy before surgery, which may have a deleterious effect on outcome, leading to myocardial infarction and mortality. This information could be provided if the authors performed a ...
Anticoagulants/*therapeutic use, Factor Xa/antagonists & inhibitors, Humans, Prodrugs/therapeutic use, Randomized Controlled Trials, Thromboembolism/drug therapy/prevention & control, Venous Thrombosis/*drug therapy/prevention & control ...
Vorapaxar is a protease activated receptor-1 (PAR-1) inhibitor, which is a new class of anti-platelet heart medication that acts on a different pathway from standard therapy, including aspirin and drugs such as clopidogrel. The trials were designed to evaluate vorapaxar for the treatment and prevention of cardiac events among patients with acute coronary syndromes and those with prior heart attack, stroke, or peripheral arterial disease.. Following the recommendation of a joint DSMB, the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2ºP-TIMI 50) trial will be continued among patients in the study who had experienced a previous heart attack or peripheral arterial disease and immediately discontinued for patients in the study who had a stroke. The trial is being led by the Thrombolysis in Myocardial Infarction (TIMI) Study Group at BWH.. We are pleased that we have gotten a green light from the Data Safety Monitoring Board to continue the trial in ...
TY - JOUR. T1 - A phase I trial of alfimeprase for peripheral arterial thrombolysis. AU - Ouriel, Kenneth. AU - Cynamon, Jacob. AU - Weaver, Fred A.. AU - Dardik, Herbert. AU - Akers, Donald. AU - Blebea, John. AU - Gruneiro, Laura. AU - Toombs, Christopher F.. AU - Wang-Clow, Fong. AU - Mohler, Margie. AU - Pena, Luis. AU - Wan, Ching Yi. AU - Deitcher, Steven R.. PY - 2005/8. Y1 - 2005/8. N2 - PURPOSE: To evaluate the safety profile, pharmacokinetics, and thrombolytic activity of alfimeprase, a novel direct-acting thrombolytic agent, in patients with chronic peripheral arterial occlusion (PAO). MATERIALS AND METHODS: In this multicenter, open-label, single-dose, dose-escalation study, 20 patients with worsening symptoms of lower extremity ischemia within 6 months of enrollment were treated with alfimeprase in five escalating dose cohorts (0.025 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.3 mg/kg, and 0.5 mg/kg) by means of intraarterial and sometimes intrathrombic pulsed infusion. The primary endpoint was ...
ST-segment myocardial infarction (STEMI) is caused by thrombotic occlusion of a major coronary artery. Rapid restoration of coronary blood flow is essential in preventing myocardial necrosis. Early reperfusion of the infarct-related artery limits infarct size and improves outcome. Achieving the shortest possible delay between symptom onset and reperfusion is therefore one of the most critical factors in the management of STEMI.. ...
From the Department of Medicine and Coagulation Unit, Department of Hematology Karolinska Institutet, Stockholm, Sweden MANAGEMENT OF HEMORRHAGIC COMPLICATIONS ASSOCIATED WITH ANTITHROMBOTIC THERAPY Ammar
Thrombotic disorders of the circulatory system represent the leading cause of morbidity, motality, and health care expenditure in the United States. Fibrinolytic and Antithrombotic Therapy provides a practical, evidence-based approach to the management of thrombotic disorders for all clinicians involved in the care of patients with these disorders.
Thrombotic disorders of the circulatory system represent the leading cause of morbidity, motality, and health care expenditure in the United States. Fibrinolytic and Antithrombotic Therapy provides a practical, evidence-based approach to the management of thrombotic disorders for all clinicians involved in the care of patients with these disorders.
lish the etiological agent and the appropriate Temporary discontinuation of PD with continuation antibiotic therapy. In addition, the type of organism of antibiotic therapy may be a reasonable adjunctive can indicate the possible source of infection. In the therapy for recurring, resistant, or relapsing infec- early days of CAPD, PD effluent was handled by labo- tions. Although the duration of this approach has not ratories as any other clinical specimen, that is, small been clearly established, durations of 7 - 28 days have amounts of fluid were cultured. Culture of large been advocated (see Pagniez et al., 1988; Locatelli amounts of fluid improves the accuracy of diagnosis et al., 1995). Variations of this approach have also been (See Sewell et al., 1990). Most methods presently proposed and include hyperconcentrated antibiotics employed incorporate either a concentration method, (antibiotic lock technique) or fibrinolytics added using filtration or centrifugation, or blood culture tech- ...
Phosphate- or citrate-buffered tirofiban vs. unfractionated heparin on the rates of thrombocytopenia and outcomes in patients with NSTE-ACS: a post ...
Find information on Tenecteplase (TNKase) in Daviss Drug Guide including dosage, side effects, interactions, nursing implications, mechanism of action, half life, administration, and more. Davis Drug Guide PDF.
N2 -naphthalenesulfonyl-L-arginine esters and amides and the pharmaceutically acceptable acid addition salts thereof which have antithrombotic properties.
TY - JOUR. T1 - Role of recombinant tissue plasminogen activator in free flap salvage. AU - Rinker, Brian D.. AU - Stewart, Daniel H.. AU - Pu, Lee Li-Qun. AU - Vasconez, Henry C.. PY - 2007/2. Y1 - 2007/2. N2 - The use of recombinant tissue plasminogen activator (rTPA) in microvascular surgery has been previously reported, but no consensus exists regarding its indications, dose, efficacy, or safety. The records of all patients undergoing free tissue transfer at one institution between 2000 and 2005 were reviewed. Patients requiring reexploration for pedicle thrombosis were identified. Chi-square and the two-sided Fishers exact tests were used to compare differences between the two groups. Two hundred seventy-five free flaps were performed in 259 patients. In 27 cases (10 percent), reexploration for impending failure was performed, and pedicle thrombosis was observed in 22 cases. In 15 cases, rTPA was administered. Ten of these flaps (67 percent) were successfully salvaged, compared to 2/7 (29 ...
In the European Cooperative Acute Stroke Study 3 (ECASS3), the efficacy of intravenous thrombolysis between 3 and 4.5 hours following onset of ischaemic stroke was investigated. Compared to the placebo group, patients treated with intravenous alteplase had a better functional outcome after 3 months (odds ratio 1.34, 95% confidence interval 1.02-1.76). The risk of symptomatic intracerebral haemorrhage was higher in the alteplase group (2.4% versus 0.3%). The time window for intravenous alteplase can be safely extended to 4.5 hours, but efforts should be made to start treatment as soon as possible, since the effectiveness ofalteplase decreases over time.
Among 7193 patients treated with intravenous tissue plasminogen activator, 516 (7·2%) died during hospitalization. Factors associated with in-hospital death were older age, male gender, National Institutes of Health Stroke Scale score, history of myocardial infarction or coronary artery disease, and history of nonvalvular atrial fibrillation. Increasing age, higher National Institutes of Health Stroke Scale score, and history of dyslipidemia were associated with symptomatic intracerebral hemorrhage. There was no difference in the rates of in-hospital death or symptomatic intracerebral hemorrhage among patients treated with intravenous tissue plasminogen activator within three-hours of time last known to be well and those treated between three and 4·5 hours after this time ...
UJIAN TAKE HOME FARMAKOTERAPI DAN TERMINOLOGI MEDIK Pengampu : dr. Luciana Kuswibawati, M.Kes. Disusun Oleh : Ema Nillafita Puri Kusuma (068115097) PROGRAM PROFESI APOTEKER FAKULTAS FARMASI UNIVERSITAS SANATA DHARMA YOGYAKARTA 2007 Penggunaan Alteplase (Recombinant Tissue Plasminogen Activator (rt-PA)) pada terapi Acute Ischemic Stroke Stroke merupakan penyebab kematian terbesar di seluruh dunia, setelah penyakit kardiovaskuler dan…
TY - JOUR. T1 - Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. AU - Del Zoppo, Gregory J.. AU - Poeck, Klaus. AU - Pessin, Michael S.. AU - Wolpert, Samuel M.. AU - Furlan, Anthony J.. AU - Ferbert, Andreas. AU - Alberts, Mark J.. AU - Zivin, Justin A.. AU - Wechsler, Lawrence. AU - Busse, Otto. AU - Greenlee, Ralph. AU - Brass, Lawrence. AU - Mohr, J. P.. AU - Feldmann, Edward. AU - Hacke, Werner. AU - Kase, Carlos S.. AU - Biller, Jose. AU - Gress, Daryl. AU - Otis, Shirley M.. PY - 1992/7. Y1 - 1992/7. N2 - An open angiography-based, dose rate escalation study on the effect of intravenous infusion of recombinant tissue plastninogen activator (rt-PA) on cerebral arterial recanalization in patients with acute focal cerebral ischemia was performed at 16 centers. Arterial occlusions consistent with acute ischemia in the carotid or vertebrobasilar territory in the absence of detectable intracerebral hemorrhage were prerequisites for treatment. After the 60-minute ...
Alteplase is the only drug licensed for acute ischemic stroke, and in this formulation, the thrombolytic agent recombinant tissue plasminogen activator (rtPA) is stabilized in a solution of L-arginine. Improved functional outcomes after alteplase administration have been shown in clinical trials, along with improved histological and behavioral measures in experimental models of embolic stroke. However, in animal models of mechanically induced ischemia, alteplase can exacerbate ischemic damage. We have systematically reviewe d the literature of both rtPA and L-arginine administration in mechanical focal ischemia. The rtPA worsens ischemic damage under certain conditions, whereas L-arginine can have both beneficial and deleterious effects dependent on the time of administration. The interaction between rtPA and L-arginine may be leading to the production of nitric oxide, which can cause direct neurotoxicity, altered cerebral blood flow, and disruption of the neurovascular unit. We suggest that alternative
TY - JOUR. T1 - Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke. AU - Ishrat, Tauheed. AU - Pillai, Bindu. AU - Ergul, Adviye. AU - Hafez, Sherif. AU - Fagan, Susan C.. N1 - Funding Information: Acknowledgments This study was supported in part by the Veterans Affairs Merit Review (SCF, BX000891 and AE, BX000347) and NIH-NINDS (SCF, NS063965 and AE, NS054688). Adviye Ergul is a research pharmacologist at the Charlie Norwood Veterans Affairs Medical Center in Augusta, Georgia. Funding Information: Conflict of interest SCF is a consultant for and has received funding from Pfizer. The contents do not represent the views of the Department of Veterans Affairs or the United States Government.. PY - 2013/12. Y1 - 2013/12. N2 - We have previously reported that angiotensin receptor blockade reduces reperfusion hemorrhage in a suture occlusion model of stroke, despite increasing matrix metalloproteinase (MMP-9) activity. We ...
Intravenous Thrombolytic Therapy clinics in Wiesbaden at the best price. Find doctors, specialized in Vascular Medicine and compare prices, costs and reviews.
Intravenous Thrombolytic Therapy clinics in France at the best price. Find doctors, specialized in Vascular Medicine and compare prices, costs and reviews.
At both the 60- and 90-minute time points, reteplase demonstrated significantly higher rates of total (TIMI grade 2 or 3) and complete (TIMI grade 3) patencies than did front-loaded alteplase. Reteplase achieved 81.8% total patency (51.2% complete) as early as 60 minutes after the start of therapy, in contrast to 66.1% (37.4% complete) in the front-loaded alteplase group. The results suggest that reteplase achieves coronary patency 30 minutes sooner than alteplase. The reteplase patency rates reported here compare favorably with those achieved with front-loaded alteplase in the TIMI 4 trial.19 In contrast to the present trial, TIMI 4 included patients only up to 6 hours after the onset of pain and excluded patients ,80 years old. Therefore, somewhat higher patency rates were to be expected.. The earliest angiographic assessment in the GUSTO trial took place at 90 minutes.5 In this trial, front-loaded alteplase achieved 80.8% total patency (53.8 complete), a result similar to the 60-minute ...
Thrombolysis is of net benefit in patients with acute ischaemic stroke, who are younger than 80 years of age and are treated within 4·5 h of onset. The third International Stroke Trial (IST-3) sought to determine whether a wider range of patients mi
TY - JOUR. T1 - The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro. AU - Mutch, N. J.. AU - Moore, Norma Ross. AU - Mattsson, C.. AU - Jonasson, H.. AU - Green, A. R.. AU - Booth, Nuala Ann. PY - 2008/1. Y1 - 2008/1. N2 - Background and purpose: Recombinant tissue-type plasminogen activator (rtPA) is the only globally approved treatment for acute ischaemic stroke. Other potential treatments might be administered with rtPA, making it important to discover whether compounds interfere with rtPA-induced lysis. We evaluated methods for examining the effect of the neuroprotectant NXY-059 on the lytic property of rtPA. Experimental approach: Plasma clot formation and lysis in the presence of rtPA and NXY-059 was measured as the change in plasma turbidity. The effect of NXY-059 on rtPA-induced lysis was similarly assessed on preformed clots. Lysis of the thrombus formed in a Chandler loop measured release of ...
Antithrombotic guidelines published by the Chest Journal, the official publication of the American College of Chest Physicians (ACCP), are continuously updated as clinically relevant information accumulates. The Evidence-Based Clinical Practice Guidelines on antithrombotic therapy and prevention of thrombosis were published in 2012. This year, the topic that has been updated pertains to antithrombotic therapy, specifically addressing prophylaxis and treatment of venous thromboembolic (VTE) disease. In this paper, I focus on these guidelines regarding the indications or lack thereof for the use of Non-vitamin K-antagonist Oral Anticoagulants (NOACS), also referred to as Direct-acting Oral Anticoagulants (DOACS ...
Questions and answers on antithrombotic therapy: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation†
This study did not primarily address the question of by which means arterial recanalization can best be achieved. Only controlled randomized trials can answer this question.24 We learned, however, that the frequency of recanalization was higher with smaller arteries and good collaterals, confirming observations by others.9 15 16 Consequently, we found that patients displaying recanalization of the MCA at 8 or 24 hours after the onset of symptoms were in better clinical condition at admission than patients without recanalization, and patients with large parenchymal hypodensity as shown by first CT had a smaller chance for arterial recanalization at 24 hours after stroke. SSS score at admission, extent of parenchymal hypodensity and brain swelling on diagnostic CT, site of occlusion, and state of collaterals correlated significantly with clinical outcome 4 weeks after stroke. It is therefore questionable whether the relation between arterial recanalization and good clinical outcome is causal or ...
In large vessel occlusion (LVO) stroke, it is unclear whether severity of ischemia is involved in early post-thrombolysis recanalization over and above thrombus site and length. Here we assessed the relationships between perfusion parameters and early recanalization following intravenous thrombolysis administration in LVO patients. From a multicenter registry, we identified 218 thrombolysed LVO patients referred for thrombectomy with both (i) pre-thrombolysis MRI, including diffusion-weighted imaging (DWI), T2*-imaging, MR-angiography and dynamic susceptibility-contrast perfusion-weighted imaging (PWI); and (ii) evaluation of recanalization on first angiographic run or non-invasive imaging 3 h from thrombolysis start. Infarct core volume on DWI, PWI-DWI mismatch volume and hypoperfusion intensity ratio (HIR; defined as Tmax ! 10 s volume/ Tmax ! 6 s volume, low HIR indicating milder hypoperfusion) were determined using a commercially available software. Early recanalization occurred in 34 (16%) patients
TY - JOUR. T1 - Early MRI Findings in Patients Receiving Tissue Plasminogen Activator Predict Outcome. T2 - Insights into the Pathophysiology of Acute Stroke in the Thrombolysis Era. AU - Chalela, Julio A.. AU - Kang, Dong Wha. AU - Luby, Marie. AU - Ezzeddine, Mustapha. AU - Latour, Lawrence L.. AU - Todd, Jason W.. AU - Dunn, Billy. AU - Warach, Steven. PY - 2004/1/1. Y1 - 2004/1/1. N2 - We measured ischemic brain changes with diffusion and perfusion MRI in 42 ischemic stroke patients before and 2 hours (range approximately 1.5 to 4.5 hours) after standard intravenous tissue plasminogen activator (tPA) therapy. The median time from stroke onset to tPA was 131 minutes. Clinical and MRI variables (change in perfusion and/or diffusion weighted lesion volume) were compared between those with excellent outcome defined as 3-month modified Rankin score (mRS) of 0 to I and those with incomplete recovery (mRS , 1). In multivariate logististic regression analysis, the most powerful independent predictor ...
Materials and Methods: Data of patients treated with IV rt-PA within 4.5 hours of symptom onset between March 2015 and January 2017 were retrospectively analyzed. Patients were divided into two groups; those with isolated MCA occlusion and those with no large vessel occlusion. Large vessel occlusion was detected with contrast-enhanced computed tomography angiography performed before IV rt-PA. Additionally, demographic and clinical data of the patients were analyzed. The clinical outcomes of the patients were determined using the modified Rankin Scale (mRS) score at 3 months after treatment ...
D. H. Roberts, C. M. Bellamy, D. R. Ramsdale; Holter Monitoring of Ventricular Arrhythmias Associated with St Segment Resolution following Treatment with Alteplase (Recombinant Tissue Plasminogen Activator) in Acute Myocardial Infarction. Clin Sci (Lond) 1 March 1993; 84 (s28): 15P. doi: https://doi.org/10.1042/cs084015P. Download citation file:. ...
Antithrombotic medications reduce thromboembolic events by inhibiting platelet aggregation and coagulation. Antiplatelet drugs and oral anticoagulants are examples of antithrombotic medications and are among the most commonly prescribed drugs in both primary and secondary care.1 Clinicians are familiar with their use, however antiplatelets and oral anticoagulants are the drug classes most commonly implicated in adverse drug reactions occurring both in the community and in hospital.23 Increasing numbers of patients have an indication for combination antiplatelet and oral anticoagulant therapy. For example, more than one million people in the UK have atrial fibrillation, of whom approximately one third also have an indication for antiplatelet therapy as secondary prevention.4 Despite the need to understand the balance between benefit and risk, there are limited randomised data investigating antithrombotic co-prescription. Current guidelines are therefore based on expert opinion and the ...
We thank the authors for this timely and concise focused update of the 2013 guidelines for early management of patients with acute ischemic stroke on endovascular treatment.1 We have a concern about the interpretation of the data on patients who were not pretreated with intravenous alteplase. In the synopsis of the Multicenter Randomized Clinical trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) study the authors state that There were too few patients who did not receive IV alteplase to draw any conclusions. Indeed, only 55 patients without previous intravenous alteplase were included in MR CLEAN. However, subgroup analysis showed a similar effect size in patients not treated with intravenous alteplase (odds ratio [OR], 2.06; 95% confidence interval [CI], 0.69-6.13]) as in patients pretreated with intravenous alteplase (OR, 1.71; 95% CI, 1.22-2.40), without statistical interaction between endovascular treatment and intravenous alteplase.2 Randomized Trial ...
HONOLULU -- Attacking a brain clot directly through an artery did not improve outcomes compared with standard intravenous tissue plasminogen activator therapy, a clinical trial found.
IST-3 collaborative group, Sandercock P, Wardlaw JM et al.The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 hours of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. Epub 2012 May 23 ...
BACKGROUND: Although pre-injury antithrombotic agents, including antiplatelets and anticoagulants, are historically associated with expansion of traumatic intraparenchymal hemorrhage (tIPH), the literature has poorly elucidated the actual risk of hematoma expansion on repeat computed tomography (CT). The objective is to determine the effect of antithrombotic agents on hematoma expansion in tIPH by comparing patients with and without pre-injury antithrombotic medication. METHODS: The volume of all tIPHs over a 5-year period at an academic Level 1 Trauma Center was measured retrospectively. The initial tIPH was divided into three equally-sized quantiles. The third tertile, representing the largest subset of tIPH, was then removed from the study population because these patients reflect a different pathophysiological mechanism that may require a more acute and aggressive level of care with reversal agents and/or operative management. Per institutional policy, all patients with small- to moderate-sized
Acute vertebrobasilar thrombosis is often associated with high mortality and prolonged disability. Therapeutic route and the time window for systemic thrombolysis in acute settings remain uncertain. We describe a case of severe acute ischemic stroke due to vertebrobasilar thrombosis who achieved rapid arterial recanalization and remarkable clinical recovery during ultrasound enhanced intravenous thrombolysis, initiated at 4.5 hours after the symptom-onset. We discuss some important issues, related to the final diagnosis, that arise due to the complete clinical recovery, rapid arterial recanalization and absence of any acute infarction on subsequent neuroimaging. © 2010 by the American Society of Neuroimaging ...
BACKGROUND: Thrombolytic drugs may dissolve blood vessel clots in acute ischemic stroke. The overall benefit of intravenous thrombolysis is substantial, but up to 2/3 of patients with large clots may not achieve re-opening of the vessel and up to 40% of the patients may remain severely disabled or die. Ultrasound accelerates clot break-up (lysis) when combined with thrombolysis (sonothrombolysis) and increases the likelihood of functional independence at 3 months. Adding intravenous ultrasound contrast (gaseous microspheres) further enhances the thrombolytic effect (contrast enhanced sonothrombolysis = CEST). Contrast enhanced ultrasound may also accelerate clot break-up in the absence of thrombolytic drugs (contrast enhanced sonolysis = CES ...
In our study, there was a clear drop in the number of AIS patients treated with intravenous tPA during the epidemic. Regardless of the time from onset, there were 683 patients admitted for stroke during epidemic and 1614 patients in the same period in 2019. The percentage of intravenous tPA eligible patients between two periods are similar as 9.81% in 2020 and 8.12% in 2019. The reduction of total tPA treated patients was likely related to the lock down of the city, which made it difficult to access medical and nonmedical transportation for stroke patients from the surrounding community hospitals to the tertiary hospitals, especially if the initial stroke symptoms were mild. In addition, modifications of the environement, such as the decrease in air pollution, work stress and decreased alcohol binge drinking might have an impact on the incidence of stroke. Further studies are required to explore this hypothesis. Furthermore, the time to the administration of intravenous tPA was longer. The DNT ...
AIMS AND OBJECTIVES: To assess the trends of intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) among patients with acute ischemic stroke (AIS) admitted to our hospital between 2012 and 2014 and investigate the effects of a 24-hours (h) stroke thrombolysis emergency treatment on the intra-hospital clinical data and outcomes of these patients treated with IV rt-PA thrombolysis. BACKGROUND: Although pre-notification of stroke by emergency medical services have been endorsed by the national recommendations and implemented in some developed countries, the development in China is limited ...
Thrombotic disorders of the circulatory system represent the leading cause of morbidity, motality, and health care expenditure in the United States. Fibrinolytic and Antithrombotic Therapy provides a practical, evidence-based approach to the management of thrombotic disorders for all clinicians involved in the care of patients with these disorders. It provides not only vital conceptual information on fibrinolytic and antithrombotic therapy, but also the means to apply it to everyday decision making and patient care. Focusing on managment guidelines and critical pathways, the text stresses practicality and usability. It will be a valuable resource for the wide range of clinicians involved in the care of patients with these disorders, including cardiologists, emergency physicians, primary care physicians, hematologists, neurologists, intensivists, pharmacists, and nurse practitioners ...
Hobbs FDR and Lip GYH Antithrombotic Therapy New drugs and management strategies a handbook for clinicians provides an overview to established and novel therapies for preventing and managing thromboembolic disorders brbrThe handbook
Antithrombotic treatment after stroke due to intracerebral haemorrhage New answers are found in the Cochrane Abstracts powered by Unbound Medicine. Available for iPhone, iPad, Android, and Web.
A new report by visiongain predicts that the overall world antithrombotic and anticoagulant drug market will reach US$24.4 billion in 2015.. The study titled Antithrombotic Anticoagulant Drugs: World Market 2012-2022 assesses drugs to treat abnormal blood clotting in humans. It predicts that the industry and market for blood thinners will soon recover from the patent expiries of two leading drugs, Plavix and Lovenox. It also says that the overall world antithrombotic treatments market will show a gradual increase in sales revenues to 2022. Supporting that expansion will be increasing disease incidence, prevalence and diagnosis, especially in the developing markets of China and India.. ...
Emberson J, Lees KR, Lyden P, et al; Stroke Thrombolysis Trialists Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014 Aug 5. Epub ahead of print 25106063 ...
Jackson, D., Earnshaw, S., Farkouh, R. A., & Schwamm, L. H. (2010, May). Cost-effectiveness of Perfusion Imaging With Computed Tomography to Identify Patients for Intravenous Thrombolysis: A Hospital Perspective. Presented at ISPOR 15th Annual International Meeting, .. ...
A new research document with title Global Antithrombotic Drugs Market Size, Status and Forecast 2022 covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like United States, EU, Japan, China, India, Southeast Asia and important players/vendors such as Sanofi, Bayer, Genentech. The report will help user gain market insights, future trends and growth prospects for forecast period of 2017-2022.
Results In all, 3184 patients were included in these analyses. Antithrombotic-associated ICH (364 patients, 11%) was not associated with a significantly increased risk of death or dependency (OR 1.38, 95% CI 0.93 to 2.04). There was no heterogeneity in the BP-lowering treatment effect on death or dependency. Among 1309 patients who underwent follow-up CT after 24 h, absolute increase in haematoma±IVH volume was larger (5.2/5.0 mL) in those with compared to those without prior antithrombotics (2.2/0.9 mL; p=0.022/0.031). Intensive BP lowering reduced haematoma±IVH growth by 4.7/7.1 mL in patients on antithrombotics versus 1.3/1.4 mL in those without, although these differences did not reach statistical significance (p homogeneity=0.104/0.059). ...
Few trials comparing primary PCI with fibrinolytic therapy enrolled adequate numbers of older patients. Existing subset analyses from trials that randomized patients to primary PCI or fibrinolytic therapy suggest that PCI is a preferred strategy in older patients. The Primary Angioplasty in Myocardial Infarction (PAMI-I) study, published in 1993, randomized patients to immediate PCI or fibrinolytic therapy (tPA). Of the 395 patients enrolled, 38% were ≥65 years and 20.5% were ≥70 years of age.36 Compared with patients who received fibrinolytic therapy, patients who underwent PCI had a trend toward fewer in-hospital deaths (2.6% versus 6.5%; P=0.06) and less death or recurrent MI (5.1% versus 12.0%; P=0.02).36 In the elderly subgroup (≥65 years of age), PCI was also associated with a lower composite of death or MI than was fibrinolytic therapy (8.6% versus 20.0%; P=0.048).65 Elderly patients were more likely to have stroke (3.3% versus 0.8%; P=0.07) or ICH (2.7% versus 0.0%; P=0.01) than ...
By Matthew E. Fink, MD, Editor SOURCE: Tsivgoulis G, Wilson D, Katsanos AH, et al. Neuroimaging and clinical outcomes of oral anticoagulant-associated intracerebral hemorrhage. Ann Neurol 2018; Sep. 26. doi:10.1002/ana.2542. [Epub ahead of print]. Intracerebral hemorrhage (ICH) is the most dangerous and feared complication of oral anticoagulation and leads to a high mortality. Although the incidence is declining because of improved treatment of hypertension, the overall number of cases is rising because of more widespread use of antithrombotic medications to respond to the increasing prevalence . . .
n. the dissolution of a blood clot (thrombus) by the infusion of a fibrinolytic agent into the blood. It may be used in the treatment of phlebothrombosis, pulmonary embolism, and coronary thrombosis. See also tissue-type plasminogen activator. ...
SINAPSE is developing a world class future in medical imaging for Scotland by drawing on the combined expertise of seven Scottish universities.
Recombinant tissue plasminogen activator (tPA) improves outcomes after stroke even in many people for whom its contraindicated, such as the elderly or those with a history of stroke and diabetes, a l
In patients with acute ischemic stroke, more distal thrombus location, greater thrombus permeability, and longer time to recanalization assessment were associated with recanalization of arterial occlusion after administration of intravenous alteplase; among patients who did not receive alteplase, ra …
p,The management of antithrombotics during the periendoscopic period is traditionally represented as a doubleedged sword for cardiologists and endoscopists. Appropriate administration prevents thromboembolic events, whereas excessive administration provokes bleeding events. Therefore, cardiologists and endoscopists must consider the risks of bleeding and thromboembolism in individual cases, before deciding whether to continue antithrombotic use. Several guidelines exist concerning antithrombotic management in Asian and Western countries. These guidelines generally classify procedural bleeding risk and thromboembolic risk into high risk and low risk groups and recommend that the two risks be weighed when managing a given patient. Moreover, they generally do not recommend interrupting antithrombotics during the periendoscopic period unless absolutely necessary; however, the details surrounding this point differ among the guidelines after several revisions. In this review, we describe the present ...
The incidence of VSR in the pre-thrombolytic era was between 1-3 percent, and has declined with the use of fibrinolytic agents to 0.2 percent(5). The time of occurrence has changed from 3-5 days from the onset of the AMI in the pre-thrombolytic era to less than 24 hours with thrombolysis(6). The known risk determinants for this complication are, advanced age, female sex, no previous smoking, anterior MI, worse killip class and, increased heart rate on admission(6). On angiography, there is a higher occurance of total occlusion of the IRA (57%), usually the LAD, less collaterals with low TIMI flow and low ejection fraction(7). The Shunt degree depends on the size of the VSD, the ratio of pulmonic vascular resistance to systemic resistance and the the contractility of both ventricules.. ...
Current available data show that about 5 to 40% of coronary patients treated with conventional doses of antithrombotic drugs do not display adequate antiplatelet response. Nowadays, aspirin remains th
Herbs for Antithrombotic. Definition of Antithrombotic Herbs. List of most effective herbs used as Antithrombotic in repertory format. Combinations of herbs are more effective than single herbs.
Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis p
... the condition may be improved with the additional use of the fibrinolytic agent, stanozol. Fibrinolytic agents use an enzymatic ...
... which inhibit the naturally occurring fibrinolytic agent, plasmin. 2) The blood of individuals has an increased ability of the ... Success in treating the primary disease has been reported using blood clot lysing agents such as anabolic steroids (e.g. ... Cryofiltration apheresis, a method to remove plasma agents by removing cold-induced precipitated material, may be an effective ... on the findings that some but not all individuals with the disorder have abnormally high levels of one or two of the agents, ...
The fibrinolytic activity is inhibited by EDTA, a metal chelator agent, which removes zinc from the molecule. Hementerin is an ... Rosenfeld, G.; Hampe, O.G.; Kelen, E.M.A. (1959). "Coagulant and fibrinolytic activity of animal venoms; determination of ... coagulant and fibrinolytic index of different species". Memórias do Instituto Butantan. 29: 143-163. Biology portal. ...
InTIME II-TIMI 17 compared the single-bolus fibrinolytic agent lanoteplase (nPA) with accelerated rtPA for the treatment of ... TIMI 31 evaluated the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST- ... CLARITY-TIMI 28 assessed the efficacy and safety of adding clopidogrel to a standard fibrinolytic regimen that includes aspirin ... MERLIN-TIMI 36 evaluated a novel anti-ischemic agent, ranolazine, in patients with acute coronary syndromes. TIMI 37A evaluated ...
August 2017). "Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment ... Plasmin is a fibrinolytic enzyme that cleaves the cross-links between polymerized fibrin molecules, causing the blood clot to ... Hilleman D, Campbell J (October 2011). "Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional ...
Cardiovascular agents, coagulation/fibrinolytic agents, immunological agents, anti-inflammatory agents, albumin-based agents, ...
... cardiotonic agents MeSH D27.505.954.411.320 - fibrinolytic agents MeSH D27.505.954.411.455 - natriuretic agents MeSH D27.505. ... fibrin modulating agents MeSH D27.505.519.421.500 - antifibrinolytic agents MeSH D27.505.519.421.750 - fibrinolytic agents MeSH ... antifibrinolytic agents MeSH D27.505.954.502.270.546 - heparin antagonists MeSH D27.505.954.502.427 - fibrinolytic agents MeSH ... antiviral agents MeSH D27.505.954.122.388.077 - anti-retroviral agents MeSH D27.505.954.122.388.077.088 - anti-hiv agents MeSH ...
... is a fibrinolytic enzyme present in the earthworm Lumbricus bimastus. It has been investigated as an experimental ... antithrombotic agent. Hu, R. (2004). "Codon optimization, expression, and characterization of recombinant lumbrokinase in goat ...
eta fibrinolytic agents (en) Arriskuak. Gutxieneko dosi hilgarria. ikusi. *1.216 mg/kg 104 mg/kg 1.216 mg/kg 294 mg/kg ...
The fibrinolytic system is closely linked to control of inflammation, and plays a role in disease states associated with ... Tissue plasminogen activator (t-PA)[3] and urokinase are the agents that convert plasminogen to the active plasmin, thus ... In a process called thrombolysis (the breakdown of a thrombus), fibrinolytic drugs are used. They are given following a heart ... Thrombolysis refers to the dissolution of the thrombus due to various agents while fibrinolysis refers specifically to the ...
Chemical and toxic agents (e.g. pharmaceutical drugs, acids, bases) react with the skin leading to skin loss and eventually ... fibrinolytic or collagenases, are used to target the various components of dead tissue.[15] In select cases, special maggot ... Wounds caused by physical agents, including physical trauma and chemical burns, can be treated with antibiotics and anti- ... Chemical removal of necrotic tissue is another option in which enzymatic debriding agents, categorised as proteolytic, ...
Arteriosclerosis obliterans has been postulated as the cause, along with errors of the clotting and fibrinolytic pathways such ... Treatment includes supportive care with analgesics and anti-inflammatory agents. Exercise should be limited as it increases ...
... is sold under the brand name Fibrimex for use as a binding agent for meat. The thrombin in Fibrimex derives from ... Bajzar L, Morser J, Nesheim M (July 1996). "TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic ...
... they are autocrine agents) or of nearby cells (i.e. they are paracrine agents). The EETs have been most studied in animal ... and/or their promotion of pro-fibrinolytic removal of blood clots. With respect to their effects on the heart, the EETs are ... Vascular contraction in the portal system is mediated by several agents: nitric oxide, carbon monoxide, prostacyclin I2, and ...
... a fibrinolytic enzyme in biochemistry and medicine Tetradecanoyl phorbol acetate (12-O-Tetradecanoylphorbol-13-acetate), a ... an aluminized polyethylene suit Thickened pyrophoric agent, triethylaluminium used as an incendiary weapon Third-party ...
Agents Used to Treat Parasitic Infections Section 18: Protozoal Infections Chapter 218: Amebiasis and Infection with Free- ... and Fibrinolytic Drugs Part 5: Infectious Diseases Section 1: Basic Considerations in Infectious Diseases Chapter 115: Approach ... Antimycobacterial Agents Section 9: Spirochetal Diseases Chapter 177: Syphilis Chapter 178: Endemic Treponematoses Chapter 179 ... Bacterial Resistance to Antimicrobial Agents Section 5: Diseases Caused by Gram-Positive Bacteria Chapter 141: Pneumococcal ...
"Antimicrobial Agents and Chemotherapy. 45 (1): 324-326. doi:10.1128/AAC.45.1.324-326.2001. PMC 90284. PMID 11120989.. ... "Enterococcus faecalis exploits the human fibrinolytic system to drive excess collagenolysis: implications in gut healing and ... "Antimicrobial Agents and Chemotherapy. 35 (8): 1626-1634. doi:10.1128/aac.35.8.1626. PMC 245231. PMID 1929336.. ... "Antimicrobial Agents and Chemotherapy. 37 (11): 2474-2477. doi:10.1128/aac.37.11.2474. PMC 192412. PMID 8285637.. ...
Levamisole is purportedly a common cutting agent. Decomposition of blood vessels including purpura is a symptom of acute ... 1993). "Psychogenic purpura with abnormally increased tPA dependent cutaneous fibrinolytic activity". International Journal of ... caused by Amyloidosis Cocaine use with concomitant use of the one-time chemotherapy drug and now veterinary deworming agent ...
This is usually with a "cytoreductive agent" (hydroxyurea, also known as hydroxycarbamide). The tendency of some practitioners ... blood histamine levels and cutaneous fibrinolytic activity before and after water challenge". Br J Dermatol. 116 (3): 329-33. ...
Coagulant and fibrinolytic activity of animal venoms; determination of coagulant and fibrinolytic index of different species. ... led to the development of new anti-hypertensive agents in humans, such as captopril, developed by Squibb under the name of ... Experimental defibrination and bothropase: a study on the fibrinolytic mechanism in vivo. Haemostasis. 1978;7(1):35-45. ...
These newer agents boast efficacy at least as well as rtPA with significantly easier administration. The thrombolytic agent ... Fibrinolytic Therapy Trialists' (FTT) Collaborative Group (1994). "Indications for fibrinolytic therapy in suspected acute ... Failure rates of thrombolytics can be as high as 50%. In cases of failure of the thrombolytic agent to open the infarct-related ... With tPa and related agents (reteplase and tenecteplase), heparin is needed to keep the coronary artery open. Because of the ...
In 1958, Todd demonstrated that endothelium in human blood vessels have fibrinolytic activity. Apelin Caveolae Cellular ... These pro- and antiangiogenic signals including integrins, chemokines, angiopoietins, oxygen sensing agents, junctional ... Todd AS (September 1964). "=Localization of fibrinolytic activity in tissues". British Medical Bulletin. 20 (3): 210-2. doi: ... Journal of Biological Regulators and Homeostatic Agents. 28 (2): 169-76. PMID 25001649. Reriani MK, Lerman LO, Lerman A (June ...
28] The fibrin is slowly dissolved by the fibrinolytic enzyme, plasmin, and the platelets are cleared by phagocytosis.[29] ... Platelets release platelet-derived growth factor (PDGF), a potent chemotactic agent; and TGF beta, which stimulates the ... Simplistically, bound and activated platelets degranulate to release platelet chemotactic agents to attract more platelets to ... and chemotactic agents. Delta granules, or dense bodies, contain ADP, calcium, serotonin, which are platelet-activating ...
The presence of a fibrinolytic enzyme in human urine was reported in 1947, without a name given for such an enzyme behind its ... Urokinase is also used clinically as a thrombolytic agent in the treatment of severe or massive deep venous thrombosis, ... Gilabert-Estelles J, Ramon LA, España F, Gilabert J, Castello R, Estelles A (2006). "Expression of the fibrinolytic components ... Macfarlane RG, Pilling J (June 1947). "Fibrinolytic activity of normal urine". Nature. 159 (4049): 779. Bibcode:1947Natur.159Q. ...
These lysine-like drugs interfere with the formation of the fibrinolytic enzyme plasmin from its precursor plasminogen by ... MeSH list of agents 82000933. ...
Moreover, there is compelling evidence that plasmin, a fibrinolytic enzyme, is able to generate bradykinin after HMWK cleavage ... Stewart JM (2003). "Bradykinin antagonists as anti-cancer agents". Current Pharmaceutical Design. 9 (25): 2036-42. doi:10.2174/ ... and bradykinin antagonists have been investigated as anti-cancer agents. Bradykinin has been proposed as an explanation for ...
"Serpin genes AtSRP2 and AtSRP3 are required for normal growth sensitivity to a DNA alkylating agent in Arabidopsis". BMC Plant ... "Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding". Blood. ... "Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent". Current Drug ... a synthetic heparin pentasaccharide as a new antithrombotic agent". Expert Opinion on Investigational Drugs. 11 (3): 397-407. ...
The newer antiplatelet agent prasugrel has minimal interaction with (es)omeprazole, hence might be a better antiplatelet agent ... A loading dose given in advance of fibrinolytic therapy, continued for at least 14 days ... "Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison" ...
溶纖維蛋白藥(英語:fibrinolytic). 纖維蛋白溶酶原激活物類:重組組織纖維溶酶原激活物(英語:Recombinant tissue plasminogen activators)(阿替普酶(英語:Tissue plasminogen ... Antiplatelet agents in secondary prevention of stroke: a perspective. Stroke; a journal of cerebral circulation. September 2005 ... Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane database of systematic reviews (Online). 2007 ... EF Reynolds (編). Aspirin and similar analgesic and anti
External agents/. occupational. lung disease. Pneumoconiosis Aluminosis. Asbestosis. Baritosis. Bauxite fibrosis. Berylliosis. ... The lung vessels contain a fibrinolytic system that dissolves clots that may have arrived in the pulmonary circulation by ...
DMPA has little or no effect on coagulation and fibrinolytic factors. In addition, progestogens by themselves at physiological ... the potential impact of antipsychotic agents". Psychoneuroendocrinology. 28: 97-108. doi:10.1016/S0306-4530(02)00129-4. ISSN ...
The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction. J Thromb Haemost 2009; 7: 14_20. ... a bacterial profibrinolytic agent with high fibrin specificity, could be a valid alternative for rt-PA in less wealthy ... culminated in the final approval of rt-PA as thrombolytic agent by the FDA on 13 November 1987. Genentech immediately started ... The controversy over whether the more expensive rt-PA was clinically superior over streptokinase as a thrombolytic agent ...
549-. ISBN 978-3-642-30725-6. The first sex steroid used as pharmacological agent was Progynon, first sold by Schering AG in ... They have been found to affect the production of a variety of coagulation and fibrinolytic factors, including increased factor ... Although estrogens influence the hepatic production of coagulant and fibrinolytic factors and increase the risk of VTE and ... Antineoplastic and Immunosuppressive Agents. pp. 170-192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8. Nathanson ...
... coagulation and fibrinolytic systems and iron homeostasis Regulate iron homeostasis (acute phase independent) Via Smads /HAMP ... cascades in lymphocytes is the secretion of molecules that can suppress altered cells or eliminate pathogenic agents, through ...
December 1993). "Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in ... can contribute to the innate immune system by their ability to increase vascular permeability and act as chemotactic agents for ...
Antiplatelet, Anticoagulant, and Fibrinolytic Drugs". In Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, ... can be further metabolized to a major class of anti-inflammatory agents, the lipoxins. In addition, PGG2 and PGH2 rearrange non ...
In melasma - tranexamic acid is sometimes used in skin whitening as a topical agent, injected into a lesion, or taken by mouth ... The Cochrane Collaboration) (2011). Henry DA (ed.). "Anti-fibrinolytic use for minimising perioperative allogeneic blood ...
Fibrinogen alpha chain LRP1 SERPINI1 tPA and plasmin are the key enzymes of the fibrinolytic pathway in which tPA-mediated ... Thrombolytic Agents, Thrombolytic Therapy for Acute Myocardial Infarction". Medscape. Tsurupa G, Medved L (January 2001). " ...
Fibrinolytic agents, sometimes referred to as plasminogen activators, are divided into the following two categories: Fibrin- ... Which types of fibrinolytic agents are used in thrombolytic therapy?) and Which types of fibrinolytic agents are used in ... Fibrinolytic agents, sometimes referred to as plasminogen activators, are divided into the following two categories:. * Fibrin- ... Which types of fibrinolytic agents are used in thrombolytic therapy?. Updated: Dec 31, 2017 ...
Frozen and lyophilized compositions for a metalloproteinase fibrinolytic agent (fibrolase or NAT), a method for preparing the ... Frozen and lyophilized compositions for a metalloproteinase fibrinolytic agent (fibrolase or NAT), a method for preparing the ... Frozen and lyophilized compositions for a metalloproteinase fibrinolytic agent (fibrolase or NAT), a method for preparing the ... The present invention relates to novel pharmaceutical compositions of a fibrinolytic agent. More specifically, the present ...
Efficacy of Fibrinolytic Agents in Complicated Pleural Effusion. *Complicated Pleural Effusion/ Empyema ... To evaluate the pleural and plasmatic levels of the fibrinolytic system markers after the treatment with alteplase vs urokinase ...
Fibrinolytic agents. Class Summary. tPA exerts an effect on fibrinolytic system to convert plasminogen to plasmin. They are ... and failure of a first agent results in either the switch to another agent or the addition of a second antiplatelet agent. ... Antiplatelet agents. Class Summary. These agents are used for secondary stroke prophylaxis after previous stroke or transient ... Selection of a particular antiplatelet agent is variable, depending on physician preference. The complication of arterial ...
Overdose most often occurs when a full dose of a fibrinolytic agent is given to a small patient with a low body weight. In ... ... Overdoses of fibrinolytic agents can cause severe hemorrhagic complications. ... Overdoses of fibrinolytic agents can cause severe hemorrhagic complications. Overdose most often occurs when a full dose of a ... What are the potential complications from overdoses of fibrinolytic agents used in thrombolytic therapy?. Updated: Dec 31, 2017 ...
Bee Venom Peptide is Anti-Fibrinolytic, Anti-Microbial Agent Secapin, a bee venom peptide, exhibits anti-fibrinolytic, anti- ... venom peptide secapin has multifunctional roles as an anti-fibrinolytic agent during fibrinolysis and an anti-microbial agent ... thus indicating the role of AcSecapin-1 as an anti-fibrinolytic agent. AcSecapin-1 also inhibited both human neutrophil and ... Here, we provide the evidence that Asiatic honeybee (Apis cerana) secapin (AcSecapin-1) exhibits anti-fibrinolytic, anti- ...
Anti-Cancer Agents in Medicinal Chemistry. Title:Anticoagulant and Fibrinolytic Drugs - Possible Agents in Treatment of Lung ... Vladimir Bobek, "Anticoagulant and Fibrinolytic Drugs - Possible Agents in Treatment of Lung Cancer?", Anti-Cancer Agents in ... Anticoagulant and Fibrinolytic Drugs - Possible Agents in Treatment of Lung Cancer?. Author(s): Vladimir Bobek. 3rd Faculty of ... The aim of this study is to review anticoagulant and fibrinolytic drugs as antitumor agents with focus on their clinical use. ...
FIBRINOLYTIC AGENTS. 2014 FIBRINOLYTIC AGENTS help in the dissolution of thrombi or blood clots. Some agents used clinically ... Turning to extrinsic fibrinolytic agents used medically to enhance or mimic the normal fibrinolytic processes, and dissolve ... Regarding intrinsic fibrinolytic factors in the body, when the intrinsic coagulation system is activated, the fibrinolytic ... It is often beneficial to give agents from two or three of these classes in concert (vide infra). ...
Fibrinolytic agents. What are fibrinolytic agents?. Fibrinolytic agents are the one which breakdown the fibrin inside the clot ... This means that fibrinolytic drugs given for fibrinolytic therapy and fibrinolytic agents act on the fibrin only. The other ... HomeClinical SubjectsMedicineThrombolytic vs Fibrinolytic vs Anticoagulant agents. Thrombolytic vs Fibrinolytic vs ... Thrombolytic agents. What are thrombolytic agents?. Thrombolytic agents break down the thrombus or clot itself. ...
There are no reports of overdosage with anagrelide, however thrombocytopenia, which can potentially cause bleeding, is expected from overdosage. Single oral doses of anagrelide at 2,500, 1,500 and 200 mg/kg in mice, rats and monkeys, respectively, were not lethal. Symptoms of acute toxicity were: decreased motor activity in mice and rats and softened stools and decreased appetite in monkeys ...
... such as fibrinolytic agents is warranted in this unprecedented public health emergency, since the risk of adverse events from ... due to higher efficacy of clot lysis with comparable bleeding risk to the other fibrinolytic agents. ... Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection. The safety and scientific validity of this study is ... Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection: A Phase 2a Clinical Trial. ...
Fibrinolytic Agents. Fibrin Modulating Agents. Molecular Mechanisms of Pharmacological Action. To Top ... The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI. The safety and ... The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute ST Elevation ... Prior to fibrinolytic administration, enoxaparin (30-mg intravenous) or Un- Fractionated Heparin (maximum 4000U, intravenous) ...
The general consensus is that the fibrinolytic system is the main defence system against thrombo-embolism on the venous side, ... fibrinolytic agents, Malmö 1980, p. 104.Google Scholar. *. Arnesen, H., Nordby, E., Andersen, P. & Godai, H.C., A comparison ... Factor VIII Fibrinolytic Activity Arterial Thrombosis Fibrinolytic System Abstract Book These keywords were added by machine ... It is even possible that the fibrinolytic system might be of importance in the early phase of thrombus formation, since forming ...
Adverse effects of fibrinolytic agents are usually minor and include discomfort during intrapleural injection, transient blood ... Three fibrinolytic agents have been used: streptokinase, urokinase, and alteplase (or tissue plasminogen activator). Urokinase ... Chest Tube Drainage With Instillation of Fibrinolytic Agents. As the effusion becomes fibrinopurulent and subsequently ... chest tube drainage with or without instillation of fibrinolytic agents, and surgery (video-assisted thoracoscopic surgery or ...
Alprostadil (prostaglandin E1) is produced endogenously to relax vascular smooth muscle and cause vasodilation. In adult males, the vasodilatory effects of alprostadil on the cavernosal arteries and the trabecular smooth muscle of the corpora cavernosa result in rapid arteriolar inflow and expansion of the lacunar spaces within the corpora. As the expanded corporal sinusoids are compressed against the tunica albuginea, venous outflow through the subtunical vessels is impeded and penile rigidity develops. This is referred to as the corporal veno-occlusive mechanism. In infants, the vasodilatory effects of alprostadil increase pulmonary or systemic blood flow ...
Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Daniel E. Hilleman, James P. Tsikouris, A ... Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. / Hilleman, Daniel E.; Tsikouris, James P ... Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov 1;27(11):1558- ... Fibrinolytic agents are the preferred pharmacologic class for the management of STEMI because of their ability to achieve ...
This review is the first to cover all the natural and recombinant thrombolytic agents used in enzyme therapy. ... The biotechnological potential of fibrinolytic enzymes in the dissolution of endogenous blood thrombi Biotechnol Prog. May-Jun ... Relatively recently, the fibrinolytic enzymes produced by microorganisms, snakes, earthworms, insects, plants, and other ... Keywords: alteplase; blood clots; desmoteplase; earthworm fibrinolytic enzymes; lanoteplase; nattokinase; recombinant tissue- ...
Recommendations for an efficient and safe use of fibrinolytic agents Article Sidebar. ... Recommendations for an efficient and safe use of fibrinolytic agents. BKK Med J [Internet]. 2012Feb.20 [cited 2020Sep.24];3(1): ... Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and ... Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic ...
Fibrinolytic Agents/adverse effects*. *Fibrinolytic Agents/therapeutic use. *Global Health. *Humans. *Incidence ...
Animal model; Cerebral hemorrhage; Fibrinolytic agents; Intraventricular; Tissue-type plasminogen activator; Urokinase-type ...
... patients with ST elevation myocardial infarction can be treated with fibrinolytic therapy. Fibrinolysis is not recommended in ... Fibrinolytic Agents. Fibrinolytic agent. Dose. Fibrin specificity*. Antigenic. Patency rate (90-minute TIMI 2 or 3 flow). ... Fibrinolytic Agents. Fibrinolytic agent. Dose. Fibrin specificity*. Antigenic. Patency rate (90-minute TIMI 2 or 3 flow). ... 4 The ACCF/AHA guideline recommends using a fibrin-specific fibrinolytic agent. Table 3 lists fibrinolytic agents currently ...
Anti-fibrinolytic Agents (Such as Tranexamic Acid, Aminocaproic Acid, or Aprotinin) Cases of fatal thrombotic complications ... 4. Longauer M. Issue Work-Up: Safety of concomitant administration of Tretinoin and anti-fibrinolytic agents. May 4, 2001. ... caution should be exercised when treating patients with the combination of tretinoin and anti-fibrinolytic agents, such as ... Agents Known to Cause Pseudotumor Cerebri/Intracranial Hypertension (Such as Tetracyclines) Tretinoin may cause pseudotumor ...
Fibrinolytic Agents / administration & dosage* * Fibrinolytic Agents / therapeutic use * Humans * Intracranial Hemorrhages / ...
Fibrinolytic Agents. Fibrin Modulating Agents. Molecular Mechanisms of Pharmacological Action. Factor Xa Inhibitors. ... Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current (index) episode of DVT and/or PE ...
FIBRINOLYTIC AGENTS; FUNCTIONS; HEART; HEAVY NUCLEI; HEMATOLOGIC AGENTS; HYDROLASES; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; ...
Antibody-directed urokinase: a specific fibrinolytic agent. By C Bode, GR Matsueda, KY Hui, E Haber ...
... delivering to the obstruction a dissolution agent which works in conjunction with blood components to effect dissolution of the ... Pharmaceutical compositions of fibrinolytic agent. US20020197246 *. Jun 21, 2002. Dec 26, 2002. Toombs Christopher F.. Method ... Pharmaceutical compositions of fibrinolytic agent. US7314728. Oct 13, 2005. Jan 1, 2008. Amgen, Inc.. Methods of treating ... Pharmaceutical compositions of fibrinolytic agent. US20070173784 *. Oct 12, 2006. Jul 26, 2007. Peter Johansson. Methods for ...
... an antithrombogenic agent, a tissue plasminogen activator, a thrombolytic agent, a fibrinolytic agent, a vasospasm inhibitor, a ... an antithrombogenic agent, a tissue plasminogen activator, a thrombolytic agent, a fibrinolytic agent, a vasospasm inhibitor, a ... or another thrombolytic agent, or mixtures thereof; a fibrinolytic agent; a vasospasm inhibitor; a calcium channel blocker, a ... or another thrombolytic agent, or mixtures thereof; a fibrinolytic agent; a vasospasm inhibitor; a calcium channel blocker, a ...
... anti-emetic agents; anti-epileptic agents; anti-estrogen agents; anti-fibrinolytic agents; anti-fungal agents; anti-glaucoma ... anti-acne agents; anti-adrenergic agents; anti-allergic agents; anti-amebic agents; anti-androgen agents; anti-anemic agents; ... anabolic agents; analeptic agents; analgesic agents; androgenic agents; anesthetic agents; anorectic compounds; anorexic agents ... anti-spasmodic agents; anti-tartar and anti-calculus agents; anti-thrombotic agents; anti-tubercular agents; antitussive agents ...
Fibrinolytic and Antithrombotic Therapy provides a practical, evidence-based approach to the management of thrombotic disorders ... 30. Fibrinolytic Agents. Appendix A. Pharmacopeia Platelet Antagonists Fibrinolytic Agents B. Drug Dosing with Renal ... 6. Fibrinolytic Agents. 7. Asprin. 8. Clopidogrel. 9. GPIIb/IIIa Receptor Antagonists. 10. Aggrenox and Cilostazol. 11. Novel ... You are here: Home Page , Medicine & Health , Clinical Medicine , Cardiovascular Medicine , Fibrinolytic and Antithrombotic ...
  • [ 20 ] When combined with fibrinolytic therapy, the use of small chest tubes was found to have some advantages over large tubes. (medscape.com)
  • FIBRINOLYTIC AGENTS help in the dissolution of thrombi or blood clots. (medicinalplants.us)
  • Relatively recently, the fibrinolytic enzymes produced by microorganisms, snakes, earthworms, insects, plants, and other organisms are being successfully used in the treatment of blood clots, especially with regard to the direct dissolving action on fibrin in tandem with less cost and side effects in comparison with the first-generation thrombolytic agents, streptokinase and urokinase. (nih.gov)
  • Fibrinolytic agents use an enzymatic action to help dissolve blood clots. (wikipedia.org)
  • Antiplatelet agents are medications that prevent blood clots from forming by inhibiting the aggregation of platelets. (medicinenet.com)
  • TXA is a generic anti-fibrinolytic agent that prevents blood clots from dissolving. (healthcanal.com)
  • Consistent with these functions, AcSecapin-1 inhibited the plasmin-mediated degradation of fibrin to fibrin degradation products, thus indicating the role of AcSecapin-1 as an anti-fibrinolytic agent. (blogspot.com)
  • Fibrinolytic agents are the one which breakdown the fibrin inside the clot but not the thrombus itself. (offlineclinic.com)
  • This means that fibrinolytic drugs given for fibrinolytic therapy and fibrinolytic agents act on the fibrin only. (offlineclinic.com)
  • It is even possible that the fibrinolytic system might be of importance in the early phase of thrombus formation, since forming fibrin may induce the platelet release reaction. (springer.com)
  • Arnesen, H., Nordby, E., Andersen, P. & Godai, H.C., A comparison between the euglobulin clot lysis time and the fibrin plate method for the estimation of fibrinolytic activity after venous stasis. (springer.com)
  • Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. (tci-thaijo.org)
  • Which fibrinolytic agent below binds to fibrin, converts plasminogen to plasmin, and is incompatible with dextrose? (studystack.com)
  • In addition, the fibrinolytic system-the system that dissolves clots-is also activated, leading to the destruction of fibrinogen and fibrin clots. (britannica.com)
  • and the non-fibrin-specific agent streptokinase, which is given over an hour. (cmaj.ca)
  • Bolus agents are easier to administer, and the fibrin-specific agents act more quickly than streptokinase 3 and have a lower mortality, especially in higher-risk cases. (cmaj.ca)
  • Heparin is a necessary conjunctive therapy with fibrin-specific agents to sustain an antithrombotic effect. (cmaj.ca)
  • Fibrinolytic and fibrin stabilizing activity of synovial membranes. (bmj.com)
  • 2 Although the (pro)fibrinolytic properties of staphylokinase were already recognized more than four decades ago, 3 its thrombolytic potential and fibrin specificity were demonstrated only recently. (ahajournals.org)
  • Fibrinolytic proteases are agents that degrade fibrin, the major component of blood thrombus. (usp.br)
  • If percutaneous coronary intervention cannot be performed rapidly, patients with ST elevation myocardial infarction can be treated with fibrinolytic therapy. (aafp.org)
  • Consequently, the majority of patients with ST elevation myocardial infarction receive fibrinolytic therapy. (bmj.com)
  • I have also checked that heparin is considered as thrombolytic, while tPA, streptokinase and urokinase are considered as fibrinolytic. (offlineclinic.com)
  • 2, 3 The use of fibrinolytic agents (streptokinase and urokinase) has recently been described in the adult literature with three small randomised controlled trials. (bmj.com)
  • Taken together, our data demonstrated that the bee venom peptide secapin has multifunctional roles as an anti-fibrinolytic agent during fibrinolysis and an anti-microbial agent in the innate immune response. (blogspot.com)
  • There are discrepancies regarding which treatment is best in clinical practice for children with parapneumonic empyema, with some authors favoring video-assisted thoracoscopy and others favoring intrapleural fibrinolytic agents. (aappublications.org)
  • Background: The role of intrapleural fibrinolytic agents in the treatment of childhood empyema has not been established. (bmj.com)
  • This study is aiming to test the hypothesis that efficacy of rhTNK-tPA was not inferior to rt-PA with respect to the 30-day MACCE rates after fibrinolytic therapy for STEMI patients. (clinicaltrials.gov)
  • The American College of Cardiology-American Heart Association (ACC-AHA) 2004 guidelines for the management of STEMI include recommendations for pharmacologic reperfusion with use of fibrinolytic agents. (elsevier.com)
  • Fibrinolytic agents are the preferred pharmacologic class for the management of STEMI because of their ability to achieve reperfusion and to restore blood flow when administered within 12 hours of symptom onset. (elsevier.com)
  • Four fibrinolytic agents are approved for the treatment of STEMI in the United States - streptokinase, alteplase, reteplase, and tenecteplase. (elsevier.com)
  • In the absence of contraindications, fibrinolytic therapy should be administered to patients with STEMI at non-PCI-capable hospitals when the anticipated first medical contact to device time at a PCI-capable hospital exceeds 120 minutes. (aafp.org)
  • Prior to fibrinolytic administration, enoxaparin (30-mg intravenous) or Un- Fractionated Heparin (maximum 4000U, intravenous) should be administered, combined with antiplatelet therapy consisted of both clopidogrel and aspirin in a 300-mg loading dose followed by routine dosage. (clinicaltrials.gov)
  • Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy. (clinicaltrials.gov)
  • Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy. (clinicaltrials.gov)
  • Note: theoretically heparin is only anticoagulant, however it works as an indirect thrombolytic agent too. (offlineclinic.com)
  • http://drsvenkatesan.com/tag/heparin-as-a-thrombolytic-agent/ with references too. (offlineclinic.com)
  • In patients treated with fibrinolytic therapy, recommendations for heparin therapy depend on the fibrinolytic agent. (slideshare.net)
  • Heparin has an established role as an adjunctive agent in patients receiving alteplase, reteplase, or tenecteplase but should not be used with nonselective fibrinolytic agents such as streptokinase and anistreplase. (slideshare.net)
  • Thrombolytic agents have been shown to increase risk of major bleeding, nonmajor bleed, and intracranial bleeding compared to heparin [ 5 ]. (hindawi.com)
  • We searched electronic databases (MEDLINE and EMBASE) from January 1980 to January 2003 and the Cochrane Library (2003, Issue 1) using the terms "pulmonary embolism," "thromboembolism," "thrombolysis," "fibrinolysis," "randomized controlled trial," "controlled clinical trial," and "random" in combination with generic and trade names of individual thrombolytic agents. (ahajournals.org)
  • To assess the clinical efficacy and safety of thrombolytic agents administered intraventricularly in the management of intraventricular hemorrhage in adults. (cochrane.org)
  • Randomized unconfounded studies comparing intraventricular fibrinolytic therapy to placebo or open control for the management of intraventricular hemorrhage in adults. (cochrane.org)
  • Thrombolytic agents break down the thrombus or clot itself. (offlineclinic.com)
  • This means, that when a thrombolytic agent encounters a clot, it starts its breakdown by directly acting on the clot. (offlineclinic.com)
  • Instead, thrombolytic agents are used instead for the breakdown of the clot. (offlineclinic.com)
  • adjusting the concentration of dissolution agent in the fluid in contact with the clot on the basis of the result of said determining step. (google.com)
  • 3. A method as defined in claim 1 wherein said step of adjusting comprises increasing the quantity of dissolution agent in he fluid in contact with the clot. (google.com)
  • However, the techniques typically employed to deliver thrombolytic agent to the site of a clot are somewhat complex and/or require the introduction of a considerable quantity of thrombolytic agent into the blood stream in view of the fact that such agent is entrained in the blood stream and thus carried away from the site of the clot, unless the clot is completely blocking the vessel. (google.com)
  • Thrombolysis: Many heart attack patients have undergone thrombolysis, a procedure that involves injecting a clot-dissolving agent to restore blood flow in a coronary artery. (heart.org)
  • Currently available treatment options for pediatric parapneumonic effusion and empyema include antibiotics alone or in combination with thoracocentesis, chest tube drainage with or without instillation of fibrinolytic agents, and surgery (video-assisted thoracoscopic surgery or open thoracotomy with decortication). (medscape.com)
  • 9 - 11 In addition to thoracotomy, 9 - 12 2 less invasive treatments have been examined: fibrinolytic agents instilled into the pleural space and video-assisted thoracoscopic surgery (VATS). (aappublications.org)
  • Two of the problems inherent in the treatment of cerebral emboli are the narrow therapeutic time window and the severe side effects of fibrinolytic drugs . (curehunter.com)
  • 10. The method of claim 2 further comprising adding a therapeutic agent to the fiber forming liquid before electrostatically spinning the fiber. (google.es)
  • There is anecdotal evidence suggesting that the intraventricular administration of fibrinolytic agents in intraventricular hemorrhage maybe of therapeutic value and safe. (cochrane.org)
  • Filamentous fungi were shown to be a good alternative for the production of fibrinolytic enzymes, among them fungi of the zygomycetes division. (usp.br)
  • So far, the evidence for a role of the fibrinolytic system in the defence against arterial thrombosis stems from observations on different patient-groups, and this evidence is steadily becoming stronger. (springer.com)
  • Stormorken H. (1984) Fibrinolytic Vessel Wall Activator in Arterial Thrombosis. (springer.com)
  • The Second Edition of Fibrinolytic and Antithrombotic Therapy, even more concise and clinically relevant than the First, provides vital, evidence-based information on management of patients with arterial and venous thrombotic disorders. (oup.com)
  • van de Loo J.C.W. (1984) Long-Term Induction of Fibrinolytic Activity in Chronic Arterial Vessel Disease. (springer.com)
  • Moreover, intravenous gaseous microspheres with ultrasound have been shown to be a potential alternative to fibrinolytic agents to recanalize discrete peripheral thrombotic arterial occlusions or acute arteriovenous graft thromboses. (biomedsearch.com)
  • 9 Antiplatelet effects of thrombin inhibitors and fibrinolytic agents. (wiley.com)
  • A recent Cochrane review 7 concluded that there was insufficient evidence to support routine use of intrapleural fibrinolytic therapy in the treatment of parapneumonic effusion and empyema. (bmj.com)
  • There have been no controlled studies of the use of fibrinolytic agents for empyema in children, but five anecdotal and short series reports have been published. (bmj.com)
  • The National Institute for Health and Clinical Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Drainage, irrigation and fibrinolytic therapy (DRIFT) for post-haemorrhagic hydrocephalus in preterm infants. (nice.org.uk)
  • There is no evidence from controlled trials of the safety and efficacy of fibrinolytic therapy for intraventricular hemorrhage. (essentialevidenceplus.com)
  • Which types of fibrinolytic agents are used in thrombolytic therapy? (medscape.com)
  • What are the potential complications from overdoses of fibrinolytic agents used in thrombolytic therapy? (medscape.com)
  • The general consensus is that the fibrinolytic system is the main defence system against thrombo-embolism on the venous side, as illustrated in Fig. 1. (springer.com)
  • The treatment of venous liposclerosis of the legs by fibrinolytic enhancement. (springer.com)
  • Various techniques for removing such obstructions are known, these techniques generally involving surgical intervention or the delivery of a dissolution agent, e.g., a thrombolytic agent. (google.com)
  • Thrombolysis medication errors: benefits of bolus thrombolytic agents. (tci-thaijo.org)
  • Ultrasound-accelerated thrombolysis is a relatively newer and safer approach that requires local administration of thrombolytic agents. (hindawi.com)
  • However, its antithrombotic effect (antiplatelet agent, anticoagulant and fibrinolytic) is little known. (scielo.cl)
  • Anticoagulant and Fibrinolytic Drugs - Possible Agents in Treatment of Lung Cancer? (eurekaselect.com)
  • The aim of this study is to review anticoagulant and fibrinolytic drugs as antitumor agents with focus on their clinical use. (eurekaselect.com)
  • However, antiplatelet drugs -normally given prophylactically - do diminish the adhesion of platelets, which reduces their potential contribution to thrombus formation (see PLATELET AGGREGATION INHIBITING AGENTS). (medicinalplants.us)
  • In this article we'll study the difference between them and also learn which drugs or agents perform each of these actions. (offlineclinic.com)
  • The interventions evaluated have included fibrinolytic agents and drugs targeting specific cell populations. (scirp.org)
  • Ninety percent of cystinosis have truncating mutations mutations a fundus of a given time.Angioplasty a medical condition deteriorates and their cause feature stridor cough and wheezing includes pulmonary oedema is the principal mechanism is restricted to the burns unit to try the above routes a drugs for other anaesthetic agents below hypothermia can be transported and positioned on his or her medical care. (nationalnewstoday.com)
  • The drugs Fibrinolytic Agents and Plasminogen have been mentioned in the context of this disorder. (malacards.org)
  • Or, it may decide to administer drugs known as fibrinolytic agents to restore blood flow. (heart.org)
  • Successful reperfusion according to the clinical evidence (EKG) should be assessed after fibrinolytic therapy.TIMI flow should be assessed for those patients with 24 hours coronary angiography. (clinicaltrials.gov)
  • From the very first randomised trials with fibrinolytic agents, angiographic substudies demonstrated the concept of early restoration of coronary patency, better preservation of left ventricular function, and improved survival. (bmj.com)
  • Turning to extrinsic fibrinolytic agents used medically to enhance or mimic the normal fibrinolytic processes, and dissolve thrombi, there are only a few agents available. (medicinalplants.us)
  • 2 . The medical device of claim 1 , wherein the anti-hypertensive bioactive agent comprises an angiotensin converting enzyme (ACE) inhibitor. (google.ca)
  • Regarding intrinsic fibrinolytic factors in the body, when the intrinsic' coagulation system is activated, the fibrinolytic system is also set in motion, and the latter involves endogenous plasminogen activators. (medicinalplants.us)
  • Adherence to the ACC-AHA guidelines, as well as knowledge about the available fibrinolytic agents, is essential for physicians and pharmacists to make informed decisions regarding appropriate pharmacologic reperfusion strategies. (elsevier.com)
  • w3 With improvements in techniques and experience, mechanical reperfusion therapy has been proven to be even more beneficial than in-hospital initiated fibrinolytic therapy. (bmj.com)
  • This review is the first to cover all the natural and recombinant thrombolytic agents used in enzyme therapy. (nih.gov)
  • The invention also relates to a novel fibrinolytic enzyme actinokinase extracted from said microorganism and to a process for the extraction of said enzyme. (freepatentsonline.com)
  • tPA exerts an effect on fibrinolytic system to convert plasminogen to plasmin. (medscape.com)
  • Following an initial eligibility screening assessment, all eligible patients who have signed the informed consent will be randomly assigned by an interactive Web-based central system for fibrinolytic therapy with either rhTNK-tPA or rt-PA. (clinicaltrials.gov)
  • Inhibition of the fibrinolytic system in Behcet disease? (springer.com)
  • This book in the new American Heart Association Clinical Series , explores and explains state-of-the-art use of antiplatelet agents and draws on the expertise of global leaders in antiplatelet therapy. (wiley.com)
  • 14 Clinical use of antiplatelet agents in cardiovascular disease: cerebrovascular diseases. (wiley.com)
  • Discontinue agents which may enhance hemorrhage risk prior to initiation of enoxaparin sodium injection or conduct close clinical and laboratory monitoring ( 2.6 , 7 ). (nih.gov)
  • Two randomized controlled pediatric clinical trials have been published comparing the effectiveness of fibrinolytic agents versus saline serum. (aappublications.org)
  • Some agents used clinically are versions of endogenous agents, and others are agents foreign to the body, with a number of modes of action. (medicinalplants.us)
  • Secondary prevention of stroke generally involves the use of antiplatelet agents, and failure of a first agent results in either the switch to another agent or the addition of a second antiplatelet agent. (medscape.com)
  • 2 Laboratory assessment of platelet function and the effects of antiplatelet agents. (wiley.com)
  • It includes up-to-date guidelines for antithrombotic and fibrinolytic therapy, and offers concise summaries of current "standards of care. (oup.com)